CoChat

A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review

Open access
Tilinca, Mariana Cornelia, Tiuca, Robert Aurelian, Burlacu, Alexandru, Varga, Andreea · 2021 · Medicina
Cited by 43

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Obesity and type 2 diabetes mellitus have become a significant public health problem in the past decades. Their prevalence is increasing worldwide each year, greatly impacting the economic and personal aspects, mainly because they frequently coexist, where the term “diabesity” may be used. The drug class of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is one of the most modern therapy options in managing these metabolic disorders. This review focuses on the effects of liraglutide, a long-acting GLP-1 RA, in diabesity and non-diabetic excess weight. This drug class improves glycemic control by enhancing insulin secretion from the beta-pancreatic cells and inhibiting glucagon release. Furthermore, other effects include slowing gastric emptying, increasing postprandial satiety, and reducing the appetite and food consumption by influencing the central nervous system, with weight reduction effects. It also reduces cardiovascular events and has positive effects on blood pressure and lipid profile. A lower-dose liraglutide (1.2 or 1.8 mg/day) is used in patients with diabetes, while the higher dose (3.0 mg/day) is approved as an anti-obesity drug. In this review, we have summarized the role of liraglutide in clinical practice, highlighting its safety and efficacy as a glucose-lowering agent and a weight-reduction drug in patients with and without diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/medicina57070669

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 26

  1. Hasanzad, 2020, A narrative review of current trends in liraglutide: Insights into the unmet needs in management of type 2 diabetes and obesity, J. Diabetes Metab. Disord., 19, 1863, 10.1007/s40200-020-00619-9 · DOI
  2. Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Grossman, A., Hershman, J.M., and Hofland, J. (2021, March 12). Definitions, Classification, and Epidemiology of Obesity, Endotext [Internet], Available online: https://www.ncbi.nlm.nih.gov/books/NBK279167/.
  3. International Diabetes Federation (2021, March 12). IDF Diabetes Atlas—9th Edition. DiabetesAtlas. Available online: http://www.diabetesatlas.org/(2019).
  4. Boles, 2017, Dynamics of diabetes and obesity: Epidemiological perspective, Biochim. Biophys. Acta Mol. Basis Dis., 1863, 1026, 10.1016/j.bbadis.2017.01.016 · DOI · Paper page
  5. Sims, 1973, Endocrine and metabolic effects of experimental obesity in man, Recent Prog. Horm. Res., 29, 457
  6. Apovian, 2019, O’Neil PM, Body Weight Considerations in the Management of Type 2 Diabetes, Adv. Ther., 36, 44, 10.1007/s12325-018-0824-8 · DOI · Paper page
  7. Canuto, 2021, Nutritional intervention strategies for the management of overweight and obesity in primary health care: A systematic review with meta-analysis, Obes. Rev., 22, e13143, 10.1111/obr.13143 · DOI · Paper page
  8. Seo, 2019, 2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea, J. Obes. Metab. Syndr., 28, 40, 10.7570/jomes.2019.28.1.40 · DOI · Paper page
  9. Holst, 2007, The physiology of glucagon-like peptide 1, Physiol. Rev., 87, 1409, 10.1152/physrev.00034.2006 · DOI · Paper page
  10. Holst, 2013, Incretin hormones and the satiation signal, Int. J. Obes., 37, 1161, 10.1038/ijo.2012.208 · DOI · Paper page
  11. Velazquez, 2018, Updates on obesity pharmacotherapy, Ann. N. Y. Acad. Sci., 1411, 106, 10.1111/nyas.13542 · DOI
  12. Vrang, 2001, Glucagon-like peptide containing pathways in the regulation of feeding behaviour, Int. J. Obes. Relat. Metab. Disord., 25, S42, 10.1038/sj.ijo.0801912 · DOI · Paper page
  13. Vrang, 1998, Glucagon-like peptide1(7-36) amide’s central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment, Diabetes, 47, 530, 10.2337/diabetes.47.4.530 · DOI
  14. Chilton, 2011, Cardiovascular comorbidities of type 2 diabetes mellitus: Defining the potential of glucagonlike peptide-1-based therapies, Am. J. Med., 124, S35, 10.1016/j.amjmed.2010.11.004 · DOI
  15. Brown, 2018, Newer GLP-1 receptor agonists and obesity-diabetes, Peptides, 100, 61, 10.1016/j.peptides.2017.12.009 · DOI
  16. Deacon, 1995, Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects, Diabetes, 44, e1131, 10.2337/diab.44.9.1126 · DOI · Paper page
  17. Abreu, 2019, Profile of semaglutide in the management of type 2 diabetes: Design, development, and place in therapy, Drug Des. Devel. Ther., 13, 731, 10.2147/DDDT.S165372 · DOI
  18. Brunton, 2020, Integrating oral semaglutide into clinical practice in primary care: For whom, when, and how?, Postgrad. Med., 132, 48, 10.1080/00325481.2020.1798162 · DOI
  19. Marre, 2009, St on behalf of the LEAD-1 SU study group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU), Diabet Med., 26, 268, 10.1111/j.1464-5491.2009.02666.x · DOI · Paper page
  20. Duan, 2019, Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis, Medicine, 98, e17860, 10.1097/MD.0000000000017860 · DOI
  21. Ueda, 2019, Use of liraglutide and risk of major cardiovascular events: A register-based cohort study in Denmark and Sweden, Lancet Diabetes Endocrinol., 7, 106, 10.1016/S2213-8587(18)30320-6 · DOI
  22. Davies, 2018, Satiety and Clinical Adiposity–Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials, Diabetes Obes. Metab., 20, 734, 10.1111/dom.13125 · DOI · Paper page
  23. Seo, 2021, Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes, J. Obes. Metab. Syndr., 30, 12, 10.7570/jomes20059 · DOI
  24. Wang, 2018, Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials, Diabetes Obes. Metab., 20, 910, 10.1111/dom.13177 · DOI
  25. Sfairopoulos, 2018, Clinical pharmacology of glucagon-like peptide-1 receptor agonists, Hormones, 17, 333, 10.1007/s42000-018-0038-0 · DOI
  26. Tsimihodimos, 2017, Antidiabetic Drugs and the Kidney, Curr. Pharm. Des., 23, 6310, 10.2174/1381612823666170307103222 · doi:10.2174/1381612823666170307103222

Cited by

See all 43

Metadata

Authors
Tilinca, M. C., Tiuca, R. A., Burlacu, A., & Varga, A.
Venue
Medicina
Publisher
MDPI AG
Published
2021-06-29
Volume
57
Issue
7
Pages
669
ISSN
  • 1010-660X (ISSN-L)
  • 1648-9144
OpenAlex
W3175253874
Cited by
43
References
36
FWCI
1.74
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review. https://app.cochat.ai/papers/10.3390/medicina57070669
The paper
Tilinca, M. C., Tiuca, R. A., Burlacu, A., & Varga, A. (2021). A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review. Medicina. https://doi.org/10.3390/medicina57070669

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.